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INTRODUCTION 1 2
The management of lung neuroendocrine tumors (NET) mainly depends on both grade of 3 differentiation (low-to intermediate vs high grade) and clinical stage at diagnosis (localized vs 4 metastatic). Surgery is the treatment of choice for low-to intermediate grade (i.e. typical or atypical 5 carcinoids) and localized tumors, while in high grade and/or disseminated lesions chemotherapy is 6 generally preferred (Pelosi et al. 2006; Garcia-Yuste et al. 2008) . Traditional therapies offer limited 7 benefits to patients with advanced disease: the traditional DNA-damaging cytotoxic agents (i.e. 8 platinum-based drugs) have low efficacy and although a large number of therapeutic options have 9 been explored, there is little consensus on a single standard treatment approach (Srirajaskanthan et 10 al. 2008) , especially in the group of clinically aggressive bronchial carcinoids. 11
Emerging data on the molecular mechanisms of carcinogenesis and tumor progression prompted 12 a new era of molecular therapeutics with the development of selective targeted agents. In this 13 context, there are several, yet poorly explored, potential therapeutic options for lung NET including 14 somatostatin analogs, inhibitors of the VEGF pathway, and inhibitors of the mammalian Target Of 15 Rapamycin (mTOR) which have shown promising activity in recent clinical studies (Duran et al. 16 2007; Kulke 2007; Yao et al. 2008) . 17 mTOR is a serine threonine kinase that participates in the regulation of proliferation, cell growth 18 and apoptosis through modulation of cell cycle progression (Vignot et al. 2005) . The activated 19 (phosphorylated) mTOR kinase leads to the subsequent phosphorylation of downstream effectors: 20 the ribosomal p70S6-kinase (S6K) and the eukaryotic initiation factor 4E-binding protein 1 21 (4EBP1), two key proteins that regulate translation of mRNAs into proteins required for cell cycle 22 progression from G1 to S phase (Podsypanina et al. 2001; Dancey 2006) . Recent insights revealed a 23 significant complexity of the mTOR pathway that seems to cross talk with other well-characterized 24 signalling cascades, thus paving the way to the use of combined therapies (Bjornsti and Houghton 25 2004; Guertin and Sabatini 2007; Meric-Bernstam and Gonzalez-Angulo 2009) . mTOR signalling 26 pathway can be upstream activated -most commonly via the PI3 Kinase/AKT pathway -by 1 receptors such as somatostatin receptors or insulin-like growth factor receptor 1 or by loss of 2 inhibiting molecules, such as PTEN (von Wichert et al. 2000; Wang et al. 2002) . Rapamycin 3 (Sirolimus, Wyeth, Philadelphia, PA) and its derivates are immunosuppressive macrolides that 4 specifically block mTOR signalling and have been shown to possess anti-proliferative activity in a 5 variety of malignancies both in vitro (Zitzmann et al. 2007 ) and in phase II clinical trials (Yao et al. 6 2008) . Inhibition of mTOR prevents phosphorylation of S6K, 4EBP1 and, indirectly, other proteins 7 involved in the transcription and cell cycle control, leading to G1 phase cell growth arrest. 8
Two rapamycin derivates have recently been evaluated in patients with NETs: Temsirolimus 9 (CCI-779; Wyeth, Madison, NJ) and Everolimus (RAD001; Novartis, Basel, Switzerland). A 10 multicentric study has recently demonstrated that Temsirolimus effectively down-regulates the 11 phosphorylation of S6K and that higher baseline levels of phospho-S6K and phospho-mTOR seem 12 to predict a better response in advanced neuroendocrine (NE) carcinomas (Duran et al. 2006), 13 although Temsirolimus does not modified the progression-free survival in advanced small cell lung 14 cancer patients (Pandya et al. 2007) . New perspectives flow from phase I trials aimed at 15 determining the safety, tolerability, pharmacokinetics and pharmacodinamics of novel mTOR 16 inhibitors such as Deforolimus (AP23573, Ariad Pharmaceuticals, Cambridge, MA), that was well 17 tolerated and showed encouraging antitumor activity (Mita et al. 2008) . Furthermore, in vitro 18 studies and in vivo clinical trials combining mTOR inhibitors and the somatostatin analog octreotide 19 have recently been published with controversial results in terms of additive anti-tumoral effects of 20 the two compounds (Grozinsky-Glasberg et al. 2008; Moreno et al. 2008; Yao et al. 2008) . 21 Despite all the above pre-clinical and clinical studies on the anti-neoplastic efficacy of mTOR 22 inhibitors in a variety of tumors, data on the activation status of mTOR signalling cascade in 23 pulmonary NET are still lacking. In this respect, a detailed protein expression map of mTOR 24 pathway-related molecules in lung NET, could not only define specific expression patterns 25 predictive of clinical response, as suggested for other malignancies (Lam et al. 2007 ), but also 26 investigate the prognostic implications of these molecules. Therefore, aim of this study was to 1 evaluate the expression of activated mTOR related proteins in a large series of pulmonary NET -2 with special reference to clinically malignant cases. Table 1 . Forty consecutive non metastatic TC were raised from 20 the files of the University of Turin to be used as control group for baseline expression of the 21 markers under evaluation. All cases were anonymized by a pathology staff member not involved in 22 the study. Clinical data were compared and analysed through coded data, only. The study was 23 approved by the institutional review board of the Hospital 24 1 Immunohistochemistry. Immunohistochemistry was performed using monoclonal antibodies 2 against Ser2448-phospho-mTOR (p-mTOR, rabbit 49F9, diluted 1/100), Thr389-phospho-p70S6K, 3 (p-S6K, mouse 1A5, diluted 1/400) and Thr37/46-phospho-4EBP1 (p-4EBP1, rabbit 236B4, diluted 4 1/300); all antibodies were purchased from Cell Signalling Technologies, Beverly, MA. Five 5 micron-thick paraffin sections were collected onto charged slides, deparaffinized and re-hydrated in 6 water. After antigen retrieval in pH 6.0 citrate buffer for 5 minutes at 125°C in a pressure cooker, 7 the relevant primary antibodies were incubated overnight at 4°C. Immunoreactions were revealed 8 by a biotin-free dextran-chain detection system (Envision, DakoCytomation, Glostrup, Denmark), 9 and developed using 3'-3'-diaminobenzidine as the chromogen. The specificity of all reactions was 10 validated in parallel control sections omitting the primary antibodies for each immunohistochemical 11 run. 12 13 Immunohistochemical data interpretation. Immunohistochemical findings were evaluated 14 independently by two of us (LR and MV) and cases with conflicting scores were reviewed jointly at 15 a multi-head microscope until a consensus was reached. All cases were evaluated using a semi-16 quantitative histological score (H-score) (Huang et al. 2005; Cappia et al. 2008) taking into account 17 both the percentage of positive tumor population within the whole section and the immunostaining 18 intensity evaluated subjectively as being negative (0), weak (1), moderate (2) and strong (3). For 19 each case, the H-score was obtained multiplying the percentages of reactive cells by the 20 corresponding immunostaining intensity obtaining a final score ranging from 0 to 300. 21
Western Blot analysis. Four lung neuroendocrine tumor cell lines (from typical -H727 -and 23
atypical -H720 -carcinoids, and from small cell carcinomas, H69 and H526) were available from 24 ATCC (Manassan, VA, USA). In addition, 14 frozen lung NET samples, not included in the present 25 series of 218 cases, were available from the tissue bank of the Pathology Unit at the University of 1 Turin. 2 All samples were homogenized and lysated in TNE lysis buffer supplemented with 1% protease 3 inhibitor cocktail (Complete, Roche Diagnostic Corporation, IN). The protein concentration was 4 evaluated using BCA protein assay Kit (Pierce, Milwaukee, WI), and 50 micrograms of protein 5 were resolved in 8% SDS-PAGE and transferred to nitrocellulose membranes for each experiment. 6
The membrane blots were blocked for 1h with 5% BSA in TBS-Tween 0,1% and incubated 7 overnight 4°C with primary antibody: anti-p-AKT (Thr 308, 1:1000), anti-p-mTOR ( Ser2884, 8 1:1000), anti-p-p70S6K (Thr 389, 1: 2000) (all from Cell Signalling Technology, Beverly, MA). 9
Anti-β-Actin (1:1000, Santa Cruz Biotechnology, Santa Cruz, CA) was used as the loading control. 10
Immunoreactive proteins were visualized using horseradish peroxidase-conjugated anti-mouse or 11 anti-rabbit antibody (1:3,000 and 1:1,000, respectively) and Enhanced Chemioluminescence (ECL) 12 (Amersham, Biosciences, Piscataway, NJ) as the substrate. 13 14 Statistical analysis. Statistical analysis was performed using Graphpad 4 software and the 15 results were considered statistically significant at a level of p<0.05. One-way ANOVA and non 16 parametric Mann-Whitney U tests were used to compare the distribution of the markers investigated 17 among the different tumor groups and with respect to clinical pathological variables. The Spearman 18 test was used to analyze the correlation index among markers expression. Overall survival analysis 19 was performed using the Kaplan-Meier method and Log-Rank test. 20
21

RESULTS
23
Distribution of mTOR signalling molecules in lung NETs. Immunohistochemical staining for 24 p-mTOR and p-4EBP1 provided the expected cytoplasmic pattern, while p-S6K showed either a 25 cytoplasmic perinuclear dot-like or a diffuse nuclear pattern of staining. 26
In peri-tumoral non neoplastic parenchyma, a weak p-mTOR, p-S6K and p-4EBP1 1 immunoreactivity was observed in normal bronchial epithelium and endothelia. Alveolar histiocytes 2 were also reactive for p-S6K and p-4EBP1, whereas a strong p-mTOR immunoreactivity was 3 detected in reactive alveolar epithelial cells at the periphery of the tumors (data not shown). 4
Distribution of p-mTOR and its downstream activation molecules was significantly different 5 among the various NET types (all p<0.0001, Figure 1 ). In particular, p-mTOR and p-S6K were 6 expressed at higher levels in low-to-intermediate grade tumors ( LG, corresponding to TC mets and 7 AC) as compared to high-grade carcinomas (HG, corresponding to LCNEC and SCLC) (p<0.001 8 and p=0.027, respectively), whereas an opposite distribution held true for p-4EBP1 in LG and HG 9 tumors, respectively (p<0.001). In the group of LG tumors, TC mets showed the highest mean H-10 score values for p-mTOR and p-4EBP1, albeit statistically not different as compared to the control 11 TC and AC groups. At variance, p-S6K H-score distribution was similar in control TC and TC 12 mets, but significantly lower in AC as compared to both TC mets and control TC (p<0.001). 13
Notably, a wide dispersion of H-score values was detected within individual tumor groups (range of 14 H-score being 0-220, 0-220, 0-170 and 0-110 for TC mets, AC, LCNEC and SCLC, respectively). 15
In the 15 cases where metastatic tumor tissue was compared to the primary lesion, no significant 16 differences were observed in terms of both the intensity and the percentage of positive cells for any 17 of the three markers under investigation. 18
Western blot analysis ( Figure 2 ) confirmed the heterogeneity of mTOR pathway activation in 19 lung NETs. Phospho-mTOR and, more markedly, p-AKT and p-S6K proteins were expressed 20 consistently in carcinoid samples, both typical and atypical. Interestingly, the two lung carcinoid 21 cell lines showed opposite activation patterns thus proving to be potential models for functional 22 tests aimed at clarifying the mechanisms of mTOR pathway activation. By contrast, in HG tumor 23 samples both p-mTOR and p-S6K were negative or weakly positive, except for one case. In parallel, 24 p-AKT expression was preserved, though to a generally lower extent, thus suggesting the activation 25 of alternative AKT-mediated signalling pathways in these tumors. 26
1 Clinical pathological associations. The distribution of p-mTOR, p-S6K and p-4EBP1 2 expression according to H-score values and clinical pathological variables is shown in Table 2 . 3
Phospho-mTOR and its downstream effectors did not correlate with proliferation or disease 4 stage. By contrast, in LG tumors high p-mTOR expression associated with parameters indicative of 5 a more favorable outcome, such as negative nodal status (in AC group, p=0.016) and disease free 6 status (p=0.005). Phospho-S6K followed the same association, although slightly below statistical 7 significance, whereas p-4EBP1 did not. Moreover, p-S6K and p-4EBP1 were expressed at higher 8 levels in small tumors, with a strong significance in LG (p-S6K, p=0.006) and HG (p-4EBP1, 9 p=0.008) tumors, respectively. 10
No association was found between p-mTOR, p-S6K and p-4EBP1 and overall survival, in either 11
LG or HG tumors. 12 13 Correlation among mTOR signalling and somatostatin receptor expression. The functional 14 activation of mTOR signalling pathway was defined by analyzing the correlation of expression 15 between p-mTOR and its downstream molecules. A strong positive correlation was observed 16 between p-mTOR and its effector p-S6K. The strong correlation was maintained in LG and HG 17 tumors when analyzed separately. Phospho-4EBP1 weakly correlated with p-mTOR but maintained 18 a significant association with p-S6K (Table 3) In the current study, we present the first evidence of activated mTOR signalling pathway in 7 pulmonary NETs, with a specific focus on aggressive forms of these tumors, which are a challenge 8 for the correct clinical management and could benefit from mTOR targeted therapies. 9
The functional activation of the PI3K/AKT/mTOR signalling pathway has never been A growing body of the literature regarding molecular drugs, such as EGFR tyrosine kinase 20 inhibitors, supports the view that the selection of patients is always the fundament to benefit from 21 these therapies at the best. Therefore, the clinical effort on the development of mTOR targeting 22 therapies should be guided by the definition of its pathway activation status within individual NETs, 23 also identifying specific profiles of pathogenetic and predictive interest. 24
In this context, immunohistochemistry is the most reliable, reproducible, cost-effective and 25 clinically applicable technique to investigate large tumor series, after assuming that specific 26 antibodies against phosphorylated (active) forms of the target molecules are used through a semi-1 quantitative evaluation. An example supporting this point of view derives from a phase II trial on 2 the effect of Temsirolimus (a rapamycin derivative) in advanced NE carcinomas. Although this 3 study concluded that this agent had little activity, not warranting further single-agent evaluation in 4 this neoplastic setting, it was clearly shown that Temsirolimus inhibited S6K phosphorylation and 5 that higher baseline levels and lower levels after therapy of p-mTOR were predictive factors of 6 better response (Duran et al. 2006) . 7
Our study demonstrates that mTOR is consistently found in pulmonary NETs of different 8 histological types, with a higher expression in low-to-intermediate grade tumors. The correlation 9 between mTOR and its downstream molecules, confirmed also by Western Blot analysis, strongly 10 supports the view that mTOR pathway is functionally activated in a subset of pulmonary NETs. 11
Such correlation was stronger and more significant with p-S6K that is directly involved in mTOR 12 signalling cascade (Guertin and Sabatini 2007) than with p-4EBP1 that, conversely, may be 13 phosphorylated by other kinases, too (Heesom et al. 2001; Wang et al. 2003) . Moreover, the 14 heterogeneous distribution of the molecules under investigation within individual histological 15 subtypes indicates the existence of different functional levels of the pathway, and reinforces the 16 contention that typing different mTOR pathway-related molecules might help to correctly select 17 patients for mTOR inhibitor-guided treatments (Meric-Bernstam and Gonzalez-Angulo 2009). In 18 this respect, a weakness of the present study is its retrospective character and the lack of clinical 19 correlates between mTOR and related molecule(s) expression, and the clinical response of patients 20 to mTOR inhibitor treatments. This limitation partly reflects the current lack of standardized 21 therapeutic approaches to the use of these drugs in the setting of clinically aggressive lung NETs. 22
Another interesting finding is the correlation that mTOR demonstrated with SSTR expression of 23 both 2A and 3 types. Biologically, this observation seems to support the view that mTOR activity 24 might be modulated also by SSTR in the light of experimental observations on octreotide capability 25 to down-regulate mTOR-upstream molecules, such as PI3 Kinase and AKT, eventually leading to 26 anti-proliferative activity (Theodoropoulou et al. 2006) . Such cross-talk between SSTRs and mTOR 1 might explain the results of recent in vitro and in vivo studies on the anti-tumoral efficacy of 2 combined mTOR inhibitor and octreotide treatment in NETs (Grozinsky-Glasberg et al. 2008; 3 Moreno et al. 2008; Yao et al. 2008) . 4
In the current tumor series, all the mTOR-related molecules failed to show a significant impact 5 on overall survival. However, higher levels of p-mTOR and p-S6K expression were associated to 6 more favorable clinico-pathological parameters; for example, they were found in LG tumor groups 7 and associated with negative nodal status (in the AC group, only) or with disease free status (in LG 8 tumor group). By contrast, 4EBP1 was unrelated to clinical pathological characteristics, suggesting 9 activation from alternative kinase pathways other than mTOR. The literature on the prognostic role 10 of mTOR pathway activation status in human tumors is scanty and controversial, supporting a 11 favorable impact in some models, such as ovarian cancer (Noske et al. 2008) , and an adverse 12 prognostic effect in others, such as renal cell (Pantuck et al. 2007; Campbell et al. 2008 ), breast 13 (Noh et al. 2008 ) and biliary tract (Herberger et al. 2007) carcinomas. However, no study was 14 previously designed to investigate the prognostic implications of mTOR pathway activation players 15 in NETs. 16
In conclusion, we first described the activation pattern of mTOR/S6K/4EBP1 signalling 17 pathway in a large series of aggressive pulmonary NETs, also providing evidence for cross-talking 18 with the SSTR pathway. These data support the concept that a detailed protein mapping of mTOR 19 pathway-related molecules in lung (and possibly other) NETs may drive a more selective strategy 20 for targeting mTOR in individual neuroendocrine tumors. 21 Abbreviations: H-s: H-score; TC mets: typical carcinoids with metastases; AC: atypical carcinoids; 1
Declaration of interest: all
LG tumors: low grade tumors, including typical carcinoids with metastases and atypical carcinoids; 2 HG carcinomas: high grade carcinomas, including large and small cell neuroendocrine carcinomas; 3 *: cut off values of Ki-67 correspond to medians in each group; NED: not evidence of disease; 4 DOC: death for other causes; AWD: alive with disease; DOD: death of disease; nr: not reached. 5 6  Table 3 . Correlation of p-mTOR, p-S6K and 4EBP-1 with somatostatin receptors 1 in 218 pulmonary neuroendocrine tumors. 
